Skip to content

A Study on the Benefits of Using Navakashya Along with Fluconazole Tablets to Treat Dadru Kustha

Randomised Clinical Control Trial Add On Effect Of Navakashya along with Fluconazole orally in management of Dadru kustha - Nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/05/087784
Enrollment
74
Registered
2025-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified

Interventions

None listed

Sponsors

Tilak Ayurved Mahavidyalaya Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Participants above 18 yrs and below 60 yrs. 2) Both males and females. 3) Cast irrespective of cast. 4) Patients with classical lakshanas of Dadru , like kandu, raga, pidaka, udagata mandal 5) Fresh cases of Dadru.

Exclusion criteria

Exclusion criteria: 1) Participants suffering with systemic disorder like uncontrolled DM, HIV, TB, cardiac, hepatic disease, Endocrinal Disorders. 2) Dadru associated with other skin disease, like Koch s, Hansen s disease, scabies, herpes zoster, diabetic wound, malignancy, eczema. 3) Steroid Folliculitis, Flexural Psoriasis, Psoriasis Vulgaris, Scabies on buttocks. 4) Patient having patches due to burning, chemical explosion. 5) Pregnancy and lactating mother. 6) Patient on steroid treatment

Design outcomes

Primary

MeasureTime frame
Improvement in clinical symptoms of Dadru kustha like kandu daha ragaTimepoint: 18 months

Secondary

MeasureTime frame
Incidence and nature of adverse drug reactions observed during and after treatmentTimepoint: 18 months

Countries

India

Contacts

Public ContactVd Shruti Ganesh Salagare

Tilak Ayurved Mahavidyalaya and Seth Tarachand Ramnath Charitable Hospital

dranupamaj.shimpi@gmail.com7387480800

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026